Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure

Damment, Stephen; Secker, Roger; Shen, Victor; Lorenzo, Victor; Rodriguez, Mariano
June 2011
Nephrology Dialysis Transplantation;Jun2011, Vol. 26 Issue 6, p1803
Academic Journal
Background. Lanthanum carbonate (FOSRENOL®, Shire Pharmaceuticals) is an effective non-calcium, non-resin phosphate binder for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). In this study, we used a rat model of chronic renal failure (CRF) to examine the long-term effects of controlling serum phosphorus with lanthanum carbonate treatment on the biochemical and bone abnormalities associated with CKD–mineral and bone disorder (CKD–MBD).Methods. Rats were fed a normal diet (normal renal function, NRF), or a diet containing 0.75% adenine for 3 weeks to induce CRF. NRF rats continued to receive normal diet plus vehicle or normal diet supplemented with 2% (w/w) lanthanum carbonate for 22 weeks. CRF rats received a diet containing 0.1% adenine, with or without 2% (w/w) lanthanum carbonate. Blood and urine biochemistry were assessed, and bone histomorphometry was performed at study completion.Results. Treatment with 0.75% adenine induced severe CRF, as demonstrated by elevated serum creatinine. Hyperphosphataemia, hypocalcaemia, elevated calcium × phosphorus product and secondary hyperparathyroidism were evident in CRF + vehicle animals. Treatment with lanthanum carbonate reduced hyperphosphataemia and secondary hyperparathyroidism in CRF animals (P < 0.05), and had little effect in NRF animals. Bone histomorphometry revealed a severe form of bone disease with fibrosis in CRF + vehicle animals; lanthanum carbonate treatment reduced the severity of the bone abnormalities observed, particularly woven bone formation and fibrosis.Conclusions. Long-term treatment with lanthanum carbonate reduced the biochemical and bone abnormalities of CKD–MBD in a rat model of CRF.


Related Articles

  • The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Pierce, David; Hossack, Stuart; Poole, Lynne; Robinson, Antoine; Van Heusen, Heather; Martin, Patrick; Smyth, Michael // Nephrology Dialysis Transplantation;May2011, Vol. 26 Issue 5, p1615 

    Background. Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate...

  • Lanthanum Carbonate: A Review of its Use in Lowering Serum Phosphate in Patients with End-Stage Renal Disease. Curran, Monique P.; Robinson, Dean M. // Drugs;2009, Vol. 69 Issue 16, p2329 

    Orally administered lanthanum carbonate (Fosrenol®) dissociates in the acid environment of the upper gastrointestinal tract to release the cation lanthanum, which then binds dietary phosphate. Lanthanum carbonate was effective in reducing levels of serum phosphate and serum calciumxphosphate...

  • Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Cozzolino, Mario; Ketteler, Markus; Martin, Kevin J.; Sharma, Amit; Goldsmith, David; Khan, Samina // Nephrology Dialysis Transplantation;Apr2014, Vol. 29 Issue 4, p899 

    Background In this Phase 4 international study, efficacy and safety of paricalcitol-centred therapy were compared with that of cinacalcet-centred therapy for the treatment of chronic kidney disease (CKD)-associated secondary hyperparathyroidism (SHPT) in patients undergoing haemodialysis...

  • Post-renal transplant calciphylaxis: treatment of hyperparathyroidism by percutaneous ethanol injection therapy and parathyroidectomy. Nam Young Park; Yeon Soon Jung; Hark Rim // NDT Plus;Feb2010, Vol. 3 Issue 1, p93 

    The article describes the case of a 50-year-old Asian woman who was diagnosed with hyperparathyroidism. The patient presented with finger calciphylaxis in her fourth and fifth distal fingers with vascular calcification of both hands. Hyperparathyroidism is a condition secondary to renal...

  • Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders. Bajait, Chaitali S.; Pimpalkhute, Sonali A.; Sontakke, Smita D.; Jaiswal, Kavita M.; Dawri, Amruta V. // Indian Journal of Pharmacology;Jan/Feb2014, Vol. 46 Issue 1, p35 

    Objectives: Patients with chronic kidney disease (CKD) suffer with multiple comorbidities and complications like secondary hyperparathyroidism and hyperphosphotemia. Altered mineral metabolism contributes to bone disease and cardiovascular disease. In patients of CKD, despite dietary phosphorus...

  • Sphingosine kinase-1: a potential mediator of renal fibrosis. Long, David A.; Price, Karen L. // Kidney International;Oct2009, Vol. 76 Issue 8, p815 

    Renal fibrosis contributes to glomerulosclerosis and tubulointerstitial damage in chronic kidney disease. A well-established pathway implicated in the progression of fibrosis is the induction of connective tissue growth factor by transforming growth factor-β, resulting in the accumulation of...

  • Mechanisms and interventions in peritoneal fibrosis. Tomino, Yasuhiko // Clinical & Experimental Nephrology;Feb2012, Vol. 16 Issue 1, p109 

    Peritoneal dialysis (PD) is an attractive treatment for patients with end-stage kidney disease (ESKD). However, long-term peritoneal dialysis is associated with development of functional and structural alterations of the peritoneal membrane. Several factors are implicated in the development of...

  • Fructokinase activity mediates dehydration-induced renal injury. Roncal Jimenez, Carlos A; Ishimoto, Takuji; Lanaspa, Miguel A; Rivard, Christopher J; Nakagawa, Takahiko; Ejaz, A. Ahsan; Cicerchi, Christina; Inaba, Shinichiro; Le, MyPhuong; Miyazaki, Makoto; Glaser, Jason; Correa-Rotter, Ricardo; González, Marvin A; Aragón, Aurora; Wesseling, Catharina; Sánchez-Lozada, Laura G; Johnson, Richard J // Kidney International;Aug2014, Vol. 86 Issue 2, p294 

    The epidemic of chronic kidney disease in Nicaragua (Mesoamerican nephropathy) has been linked with recurrent dehydration. Here we tested whether recurrent dehydration may cause renal injury by activation of the polyol pathway, resulting in the generation of endogenous fructose in the kidney...

  • Progenitor-like cells derived from mouse kidney protect against renal fibrosis in a remnant kidney model via decreased endothelial mesenchymal transition. Chen, C. L.; Chou, K. J.; Fang, H. C.; Hsu, C. Y.; Huang, W. C.; Huang, C. W.; Huang, C. K.; Chen, H. Y.; Lee, P. T. // Stem Cell Research & Therapy;12/2/2015, Vol. 6, p1 

    Introduction: Pathophysiological changes associated with chronic kidney disease impair angiogenic processes and increase renal fibrosis. Progenitor-like cells derived from adult kidney have been previously used to promote regeneration in acute kidney injury, even though it remained unclear...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics